Oncology

Samyukta Mullangi, MD, MBA, oncology fellow at Memorial Sloan Kettering Cancer Center and incoming medical director at Thyme Care, spoke on financial toxicity, heterogeneity of cancer, and other complex factors in oncology care systems that may perpetuate disparities in health care outcomes and delivery among patients.

Olalekan Ajayi, PharmD, MBA, chief operating officer of Highlands Oncology Group, PA, and 2023-2024 president-elect of the Association of Community Cancer Centers (ACCC), discusses why he is excited for this year’s meeting, including its many workshops and day 1 keynote on CRISPR.

Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model kicks off on July 1.

David A. Eagle, MD, New York Cancer & Blood Specialists, discusses the present state of treatment for cancer, which often sees patient financial concerns outweighed by the cost of treatment.

Utilizing real-world evidence that applies to the specific care needs of certain patient populations can promote timely decision-making among payers and providers on the use of effective cancer therapies available on the market, said panelists at the 2022 Patient-Centered Oncology Care® (PCOC) meeting.

Coverage from the January 18, 2023, Institute for Value-Based Medicine session with Regional Cancer Care Associates held in New Brunswick, New Jersey.

Richard L. Martin III, MD, MPH, medical director for Health Equity and Community Engagement, Tennessee Oncology; president, Tennessee Oncology Practice Society.

At Carolina Blood and Cancer Care Associates, the No One Left Alone (NOLA) initiative is working to break down cancer health disparities among its patients by addressing the social determinants of health that may be preventing equitable access to care.

A novel algorithm based on patient-reported outcome questionnaires stratified patients by disease complexity and effectively identified those at a higher risk of having an acute care visit.

Whitney Jones, MD, chief medical advisor at GRAIL Inc, discusses the PATHFINDER study of multi-cancer early detection testing.

The findings emphasize a need for policies that may offset the impact of direct and indirect costs for patients with breast cancer.

Five leading academic cancer centers are assessing the feasibility of implementing the Health Equity Report Card pilot project as a tool that can both meaningfully and feasibly measure and report on equitable care practices.

The approval is based on results from the phase 3 TROPiCS-02 trial demonstrating overall and progression survival benefits with sacituzumab govitecan compared with physician’s choice of single-agent chemotherapy.

A review and meta-analysis published in the journal Radiology found MRI to be the most effective supplemental breast cancer screening method for women with dense breasts and negative mammogram results.

Colon carcinoma and acute diverticulitis have similar computed tomography imaging features that can make differential diagnosis difficult for radiologists, but a novel artificial intelligence assistance model was shown to help diagnostic accuracy.

The findings suggest that both high-risk patients and high-risk regions should be considered in clinical and policy strategies to facilitate timely breast cancer care.

Patient quality of life can be improved through shared knowledge between doctors and patients in cancer care using the Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Tool calculator, which Rocky Mountain Cancer Centers piloted, explained Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.

Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.

A preplanned analysis of the PACIFIC-R confirms findings from the pivotal PACIFIC trial of durvalumab as consolidation therapy in unresectable NSCLC after chemoradiotherapy.